Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation

British Journal of Pharmacology

Volumn 137, Issue 6, 2002, Pages 837-844

  Francischi, J N ^a   Chaves, C T ^a   Moura, A C L ^a   Lima, A S ^a   Rocha, O A ^a   Ferreira Alves, D L ^a   Bakhle, Y S ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

COX 1 and COX 2 inhibitors; Cyclo oxygenases; Hyperalgesia; Hypoalgesia; Paw oedema

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PIROXICAM; PROSTAGLANDIN; ROFECOXIB; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HYPERALGESIA; HYPOALGESIA; MALE; NONHUMAN; PAIN THRESHOLD; PAW EDEMA; PLANTARIS MUSCLE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT;

ANIMALS; CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; HINDLIMB; HYPERALGESIA; INDOMETHACIN; INFLAMMATION; ISOENZYMES; LACTONES; MALE; PAIN THRESHOLD; PIROXICAM; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; SULFONAMIDES; SULFONES;

EID: 0036857615     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704937     Document Type: Article

References (24)

1. Bakhle, Y.S. & Botting, R.M. (1996). Cyclooxygenase-2 and its regulation in inflammation. Mediat. Inflamm., 5, 305-323.
2. Ballou, L.R., Botting, R.M., Goorha, S., Zhang, J. & Vane, J.R. (2000). Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 97, 10272-10276.
3. Bombardier, C. (2002). An evidence-based evaluation of the gastrointestinal safety of coxibs. Am. J. Cardiol., 89, 3D-9D.
4. Chan, C.C., Boyce, S. & Brideau, C. (1999). Rofecoxib (Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone: A potent and orally active cyclooxygenase inhibitor. Pharmacological and biochemical profiles. J. Pharm. Exp. Ther., 290, 551-560.
5. Collier, H.O. & Schneider, C. (1972). Nociceptive response to prostaglandins and analgesic actions of aspirin and morphine. Nature New Biology, 236, 141-143.
6. Ferreira, S.H. (1972). Prostaglandins, aspirin-like drugs and analgesia. Nature New Biology, 240, 200-203.
7. Ferreira, S.H. (1990). A classification of peripheral analgesics based upon their mode of action. In: Sander, M., Collins, G.M. (eds). Migraine: A Spectrum of Ideas. New York: Oxford University Press, pp. 59-72.
8. Francischi, J.N., Chaves, C.T., Lima, A.S. & Bakhle, Y.S. (2002). A new anti-nociceptive pathway mediated by cyclooxygenase-2 in rat paw inflammation induced by carrageenan. Br. J. Pharmacol., 135, 159P.
9. Guo, X., Liu, E.S., Ko, J.K., Wong, B.C., Ye, T., Lam, S. & Cho, C. (2001). Protective role of cyclooxygenase inhibitors in the adverse action of passive smoking on the initiation of experimental colitis in rats. Eur. J. Pharmacol., 411, 193-203.
10. Hawkey, C.J. (1999). COX-2 inhibitors. Lancet, 353, 307-314.
11. Mazario, J., Gaitan, G. & Herrero, J.F. (2001). Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology, 40, 937-946.
12. Penning, T.D., Talley, J.J., Bertenshaw, S.R., Carter, J.S., Collins, P.W., Docter, S., Graneto, M.J., Lee, L.F., Malecha, J.W., Miyashiro, J.M., Rogers, R.S., Rogier, D.J., Yu, S.S., Anderson, G.D., Burton, E.G., Cogburn, J.N., Gregory, S.A., Koboldt, C.M., Perkins, W.E., Seibert, K., Veenhuisen, A.W., Zhang, Y.Y. & Isakson, P. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem., 40, 1347-1365.
13. Randall, L.D. & Selitto, J.J. (1957). A method for measurement of analgesic activity on inflamed tissues. Arch. Int. Pharmacodyn., 113, 233-249.
14. Samad, T.A., Moore, K.A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., Bonventre, J.V. & Woolf, C.J. (2001). Interleukin-1 beta mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature, 410, 471-475.
15. Smith, J.M., Zhang, Y., Koboldt, C.M., Muhammad, J., Zweifel, B.S., Shaffer, A.F., Talley, J.J., Masferrer, J., Seibert, K. & Isakson, P. (1998). Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U.S.A., 95, 13313-13318.
16. Svensson, C.I. & Yaksh, T.L. (2002). The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu. Rev. Pharmacol. Toxicol., 42, 553-583.
17. Vane, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature, 231, 232-235.
18. Vane, J.R., Bakhle, Y.S. & Botting, R.M. (1998). Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 38, 97-120.
19. Vanegas, H. & Schaible, H.G. (2001). Prostaglandins and cyclooxygenases in the spinal cord. Prog. Neurobiol., 64, 327-363.
20. Warner, T.D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J.A. & Vane, J.R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A., 96, 7563-7568.
21. Williams, T.J. & Morley, J. (1973). Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature, 246, 215-217.
22. Williams, T.J. & Peck, M.J. (1977). Role of prostaglandin-mediated vasodilatation in inflammation. Nature, 270, 530-532.
23. Yamagata, K., Andreasson, K.I., Kaufman, W.E., Barnes, C.A. & Worley, P.F. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids. Neuron, 11, 371-386.
24. Zimmerman, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 16, 109-110.